Paper: Sanofi bid for Piramal falters

Sanofi-Aventis' plans to buy a majority stake in India's Piramal Healthcare has fallen through because of a disagreement over valuation, sources familiar with the potential deal told the Economic Times. Report

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.